A Phase Ib Study of Yervoy With Sylatron for Patients With Unresectable Stages IIIB/C/IV Melanoma.
Phase of Trial: Phase I
Latest Information Update: 02 May 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ipilimumab
- Indications Malignant melanoma
- Focus Adverse reactions
- 20 Mar 2017 Status changed from active, no longer recruiting to completed.
- 23 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Jul 2017.
- 17 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Mar 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History